CoChat

Frameworks for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging Processes

Open access
Justice, Jamie, Miller, Jordan D., Newman, John C., Hashmi, Shahrukh K., Halter, Jeffrey, Austad, Steve N., Barzilai, Nir, Kirkland, James L. · 2016 · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Therapies targeted at fundamental processes of aging may hold great promise for enhancing the health of a wide population by delaying or preventing a range of age-related diseases and conditions-a concept dubbed the "geroscience hypothesis." Early, proof-of-concept clinical trials will be a key step in the translation of therapies emerging from model organism and preclinical studies into clinical practice. This article summarizes the outcomes of an international meeting partly funded through the NIH R24 Geroscience Network, whose purpose was to generate concepts and frameworks for early, proof-of-concept clinical trials for therapeutic interventions that target fundamental processes of aging. The goals of proof-of-concept trials include generating preliminary signals of efficacy in an aging-related disease or outcome that will reduce the risk of conducting larger trials, contributing data and biological samples to support larger-scale research by strategic networks, and furthering a dialogue with regulatory agencies on appropriate registration indications. We describe three frameworks for proof-of-concept trials that target age-related chronic diseases, geriatric syndromes, or resilience to stressors. We propose strategic infrastructure and shared resources that could accelerate development of therapies that target fundamental aging processes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/gerona/glw126

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Pipeline of drug development for interventions that target fundamental aging processes. As in other fields, numerous potential interventions will be winnowed in the preclinical phase, with those showing the most promise for targeting the biology of aging progressing to initial safety studies in humans. Small proof-of-concept clinical trials might then “de-risk” these candidate interventions by providing signals of efficacy and further safety data to better predict success in large clinical trials designed to support Food and Drug Administration approval.
Figure 1. Pipeline of drug development for interventions that target fundamental aging processes. As in other fields, numerous potential interventions will be winnowed in the preclinical phase, with those showing the most promise for targeting the biology of aging progressing to initial safety studies in humans. Small proof-of-concept clinical trials might then “de-risk” these candidate interventions by providing signals of efficacy and further safety data to better predict success in large clinical trials designed to support Food and Drug Administration approval.CC BY-NC-ND · PubMed Central
Figure 2. Frameworks and goals for proof-of-concept clinical trials of interventions that target fundamental aging processes. These interventions are hypothesized to affect multiple age-related diseases and conditions: the “geroscience hypothesis.” Three frameworks are presented for the design of clinical trials to test these interventions for effects on outcomes related to age-related diseases, geriatric syndromes, and resiliency. Proof-of-concept clinical trials would test the geroscience hypothesis, but also provide evidence of efficacy in the outcome being targeted, as well as data and samples for further research. Ultimately, proof-of-concept trials will help justify and in the design of larger clinical trials and support new regulatory indications for interventions that target fundamental aging processes.
Figure 2. Frameworks and goals for proof-of-concept clinical trials of interventions that target fundamental aging processes. These interventions are hypothesized to affect multiple age-related diseases and conditions: the “geroscience hypothesis.” Three frameworks are presented for the design of clinical trials to test these interventions for effects on outcomes related to age-related diseases, geriatric syndromes, and resiliency. Proof-of-concept clinical trials would test the geroscience hypothesis, but also provide evidence of efficacy in the outcome being targeted, as well as data and samples for further research. Ultimately, proof-of-concept trials will help justify and in the design of larger clinical trials and support new regulatory indications for interventions that target fundamental aging processes.CC BY-NC-ND · PubMed Central
Figure 3. Proposed development of shared resources and strategic infrastructure to accelerate progress through early clinical trials of interventions targeting fundamental aging processes. Many of these shared resources might be coordinated by new Geroscience Translational Network Centers, which would specialize in particular aspects of preclinical basic research, clinical trial support, and training.
Figure 3. Proposed development of shared resources and strategic infrastructure to accelerate progress through early clinical trials of interventions targeting fundamental aging processes. Many of these shared resources might be coordinated by new Geroscience Translational Network Centers, which would specialize in particular aspects of preclinical basic research, clinical trial support, and training.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 105

Metadata

Authors
Justice, J., Miller, J. D., Newman, J. C., Hashmi, S. K., Halter, J., Austad, S. N., Barzilai, N., & Kirkland, J. L.
Affiliations
  • Wake Forest University Health Sciences (US)
  • Mayo Clinic (US)
  • University of California, San Francisco (US)
  • University of Michigan (US)
  • University of Alabama at Birmingham (US)
  • Albert Einstein College of Medicine (US)
Corresponding author
  • Justice, Jamie
  • Miller, Jordan D.
  • Newman, John C.
Venue
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
Published
2016-08-16
Volume
71
Issue
11
Pages
1415-1423
ISSN
  • 1079-5006 (ISSN-L)
  • 1758-535X
OpenAlex
W2513348288
Cited by
96
References
55
Citations by year
2026: 9 · 2025: 9 · 2024: 12 · 2023: 7 · 2022: 4 · 2021: 14 · 2020: 14 · 2019: 10 · 2018: 10 · 2017: 6 · 2016: 1
FWCI
4.85
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • The Journals of Gerontology Series A (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
NIH (R24AG044396)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Social Sciences › Psychology › Developmental and Educational Psychology › Aging and Gerontology Research
Keywords
anti-aging therapy, age-related chronic diseases, geriatric syndromes, research networks, shared research resources
MeSH terms
Aged, Aging, Animals, Chronic Disease, Clinical Trials as Topic, Congresses as Topic, Disease Models, Animal, Humans, Longevity, Research Design, Biomarkers, Disease Progression, Biomedical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Frameworks for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging Processes. https://app.cochat.ai/papers/10.1093/gerona/glw126
The paper
Justice, J., Miller, J. D., Newman, J. C., Hashmi, S. K., Halter, J., Austad, S. N., Barzilai, N., & Kirkland, J. L. (2016). Frameworks for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging Processes. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. https://doi.org/10.1093/gerona/glw126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.